The search for a new business model for #StemCell therapies and regenerative medicine

In recent years there has been tremedous progress in the field of cell therapy and in understanding multipotent mesenchymal stromal cells (MSC). Promising results are available from numerous clinical trials using MSC and MSC-like cells. Discover more about them from Monika, Baehner, Head of Project Management Therapeutic Cell Initiative Pharma Research and Early Development (pRED), Roche, Germany.

Monika Baehner, PhD is the Head of Project Management, Therapeutic Cell Initiative (TCI), Roche Pharma Research and Early Development (pRED), Germany. Dr. Baehner received her PhD in Biology at the University of Karlsruhe, Germany in 2001. She started her career at m-phasys GmbH aiming to refold membrane proteins for structure based drug design. After joining Roche in 2005 she became responsible for the early development of therapeutic proteins and especially antibodies. Since 2010 she is leading the Project Management team within TCI. This initiative comprises all activities on (stem) cells for therapeutic use and clinical application and will leverage and explore (stem) cells together with external partners of excellence.

To find out more, click here to download the slides as presented at World Stem Cells & Regenerative Medicine Congress Asia 2011.

Also, visit us at World Stem Cells & Regenerative Medicine Congress 2012 to gain more valuable insights. Feel free to contact us for more details!